Adverum Biotechnologies

ADVM71

High Growth

$6.86arrow_drop_down4.96%-$0.36

High Growth

ADVM71

$6.86

arrow_drop_down4.96%-$0.36

High Growth

Performance History

Key Stats
Open	$7.64
Prev. Close	$7.56
EPS	-5.95
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$153.83M
PE Ratio	-

	LOW	HIGH
Day Range	7.25	7.63
52 Week Range	6.38	29.70

Ratios







EPS	-5.95

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc (ADVM) is a biotechnology company that focuses on developing gene therapies for ocular and rare diseases. The company's primary product candidate, ADVM-022, is a novel gene therapy designed to treat wet age-related macular degeneration (wet AMD), a leading cause of blindness worldwide. ADVM-022 utilizes the company's proprietary vector platform to deliver a therapeutic gene to the retina, with the goal of reducing the frequency of intravitreal injections required for current treatments.

In terms of stock performance, Adverum Biotechnologies Inc (ADVM) has seen its share price fluctuate over the years. The stock has experienced both significant gains and losses, reflecting the volatility of the biotech sector. Investors should carefully evaluate the company's financial health, pipeline of product candidates, and market potential before considering an investment in ADVM. It is important to note that investing in biotech stocks can be highly speculative and carries significant risks.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Laurent Fischer
Headquarters: Redwood City
Employees: 123
Exchange: NASDAQ

add Adverum Biotechnologies to watchlist

Keep an eye on Adverum Biotechnologies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Adverum Biotechnologies 's (ADVM) price per share?

The current price per share for Adverum Biotechnologies (ADVM) is $6.86. The stock has seen a price change of -$0.36 recently, indicating a -4.97% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Adverum Biotechnologies (ADVM)?

For Adverum Biotechnologies (ADVM), the 52-week high is $29.7, which is 332.94% from the current price. The 52-week low is $6.38, the current price is 7.52% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Adverum Biotechnologies (ADVM) a growth stock?

Adverum Biotechnologies (ADVM) has shown an average price growth of -4.94% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Adverum Biotechnologies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Adverum Biotechnologies (ADVM) stock price performance year to date (YTD)?

As of the latest data, Adverum Biotechnologies (ADVM) has a year-to-date price change of -17.16%. Over the past month, the stock has experienced a price change of -10.79%. Over the last three months, the change has been 5.05%. Over the past six months, the figure is -21.6%. Looking at a longer horizon, the five-year price change stands at -92.68%.

help

Is Adverum Biotechnologies (ADVM) a profitable company?

Adverum Biotechnologies (ADVM) has a net income of -$117.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.92K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.6M, although specific revenue growth data is currently not available. Operating income is noted at -$123.79M. Furthermore, the EBITDA is -$99.02M.

help

What is the market capitalization of Adverum Biotechnologies (ADVM)?

Adverum Biotechnologies (ADVM) has a market capitalization of $142.7M. The average daily trading volume is 6.98, indicating the stock's liquidity and investor engagement.